MFC엠에프씨

Quick answers about MFC

What does MFC do?

The company is a Korean specialist in developing and manufacturing active pharmaceutical ingredients (APIs) and their key starting materials and intermediates, using organic synthesis, scale-up production and novel crystallization technologies. Its main business covers APIs and core materials for generic drugs, sold to pharmaceutical customers and covering areas such as cardiovascular, digestive, musculoskeletal and diabetes treatments, and it also develops new crystalline-form and salt-form improved drug ingredients that are patent-protected. The company operates through its manufacturing facilities in Korea and sells products to pharmaceutical makers, with a filing registering 37 APIs with Korea's food and drug safety ministry.

What is the market cap of MFC?

The market capitalisation of MFC was ₩21B at the close on Oct 27, 2026.

Who are the largest shareholders of MFC?

According to the latest official filings, the largest reported holders are Hwang Sung-kwan (41.34%, as of Jun 10, 2026); JW Pharmaceutical (9.17%, as of Jan 3, 2025); Huons Global (5.17%, as of Jan 3, 2025).

When is the next earnings report from MFC?

Korean companies rarely announce results dates in advance. Based on when MFC filed the same report in past years, its next 3q results is expected around Nov 14, 2026.